Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Liabilities and Shareholders Equity (2016 - 2025)

Kiora Pharmaceuticals' Liabilities and Shareholders Equity history spans 11 years, with the latest figure at $24.3 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 33.52% year-over-year to $24.3 million; the TTM value through Dec 2025 reached $120.1 million, down 24.12%, while the annual FY2025 figure was $24.3 million, 33.52% down from the prior year.
  • Liabilities and Shareholders Equity reached $24.3 million in Q4 2025 per KPRX's latest filing, down from $29.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $42.4 million in Q1 2024 to a low of $13.7 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $25.3 million, with a median of $20.8 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 175.75% in 2021, then crashed 33.52% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $20.1 million in 2021, then decreased by 12.26% to $17.7 million in 2022, then decreased by 22.37% to $13.7 million in 2023, then surged by 166.08% to $36.5 million in 2024, then tumbled by 33.52% to $24.3 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Liabilities and Shareholders Equity are $24.3 million (Q4 2025), $29.9 million (Q3 2025), and $31.9 million (Q2 2025).